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Abstract
Purpose: Translocation renal cell carcinoma (tRCC) represents a rare subtype of kidney cancer 
associated with various TFE3, TFEB, or MITF gene fusions that is not responsive to standard 
treatments for RCC. Therefore, the identification of new therapeutic targets represents an unmet 
need for this disease.
Experiment design: We have established and characterized a tRCC patient-derived xenograft 
(PDX), RP-R07, as a novel preclinical model for drug development by using next generation 
sequencing and bioinformatics analysis.We then assessed the therapeutic potential of inhibiting the 
identified pathway using in vitro and in vivo models.
Results: The presence of a SFPQ-TFE3 fusion (t(X;1) (p11.2; p34)) with chromosomal break-
points was identified by RNA-seq and validated by RT-PCR. TFE3 chromatin 
immunoprecipitation followed by deep sequencing (ChIP-Seq) analysis indicated a strong 
enrichment for the PI3K/AKT/mTOR pathway. Consistently, microRNA microarray analysis also 
identified PI3K/AKT/mTOR as a highly enriched pathway in RP-R07. Upregulation of PI3/AKT/
mTOR pathway in additional TFE3-tRCC models were confirmed by significantly higher 
expression of phospho-S6 (P<0.0001) and phospho-4EBP1 (P<0.0001) in established tRCC cell 
lines compared to clear cell RCC cells. Simultaneous vertical targeting of both PI3K/AKT and 
mTOR axis provided a greater anti-proliferative effect both in vitro (P<0.0001) and in vivo 
(P<0.01) compared to single node inhibition. Knockdown of TFE3 in RP-R07 resulted in 
decreased expression of IRS-1 and inhibited cell proliferation.
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Conclusion—These results identify TFE3/IRS-1/PI3K/AKT/mTOR as a potential dysregulated 
pathway in TFE3-tRCC, and suggest a therapeutic potential of vertical inhibition of this axis by 
using a dual PI3K/mTOR inhibitor for TFE3-tRCC patients.
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INTRODUCTION
Micropthalmia transcription factor (MiT) family tRCC is a distinct subtype of kidney cancer 
characterized by gene fusions resulting from translocations involving TFE3 (Xp11.2 locus 
(1) or TFEB (6p21 locus) (2) with various partner gene (3). Since its introduction as a 
separate clinical entity in the 2004 World Health Organization classification of renal tumors, 
tRCC has gained increasing recognition in clinical practice. It is estimated that 1/3 of 
pediatric RCCs, 15% of RCCs in patients < 45 years of age (4), and up to 4% of adult RCCs 
overall may have MiT family translocations (5). However, despite the clinical burden that 
tRCC presents, there is a paucity of data regarding effective management (6).
Despite the identification of multiple TFE3 gene fusions in tRCC including PSF-TFE3, 
NONO-TFE3, PRCC-TFE3(7), ASPL-TFE3(8), CLTC-TFE3(9), and recent novel fusion 
TFE3-DVL-2 (10) and TFE3-RBM10(11), the molecular mechanisms underpinning tRCC 
oncogenesis are not well understood (3). Moreover, the heterogeneity of the dysregulated 
signaling pathways resulting from the variety of TFE3 gene fusions, combined with the lack 
of drugs targeting the chimeric oncoproteins, poses additional challenges to establish 
effective treatments. Genetically engineered cell lines (12), as well mouse models (13), have 
been generated to study the biology of various tumors harboring TFE3 fusions. However, 
more researchers are turning to patient-derived xenograft (PDX) models, which maintain the 
fidelity of the original tumor, including genomic integrity, tumor heterogeneity, and potential 
therapeutic responsiveness (14). Therefore, a PDX model can provide a translatable 
representation of tRCC in the laboratory setting that allows improving our understanding of 
tumorigenesis and the real-world applicability of treatment options.
Identifying the target genes and DNA binding landscape of TFE3 is critical to characterize 
its functional role as a transcription factor in a complex gene regulatory network. To date, 
studies utilizing next generation sequencing (NGS) technology have reported TFE3 target 
genes and DNA binding profile in embryonic stem cells (15), mouse embryonic fibroblasts 
(16), and melanoma cells (17). However, to the best of our knowledge, the target genes and 
DNA binding profile of TFE3 in tRCC cells have not yet been reported. Chromatin 
immunoprecipitation followed by deep sequencing (ChIP-Seq), an application of next NGS, 
provides an efficient method for global profiling of DNA-binding proteins and identification 
of their target sites on a genome wide scale. Therefore, ChIP-Seq is a valuable tool that 
could be used to gain novel biological insight of TFE3 gene regulatory networks and 
oncogenic pathways in tRCC.
In addition to transcription factors, microRNAs (miRNA) also play an integral role in a 
tightly controlled genetic regulatory system. MiRNAs are short, non-coding RNA molecules 
Damayanti et al. Page 2
Clin Cancer Res. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
that post-transcriptionally target messenger RNA (mRNA) to modulate gene expression (18). 
In highly inter-connected network, both transcription factors and miRNA work to orchestrate 
cascade and/or combined regulatory functions to facilitate cellular physiology (19). 
Therefore, analysis of both the miRNA and transcription factor regulatory network are 
pertinent in the identification of key genomic elements and their associated pathways. 
Furthermore, dysregulated miRNAs have been frequently implicated in carcinogenesis (20). 
Thus, their expression profile is of particular importance in oncology to aid in biomarker 
selection (21), cancer classification, and molecular target identification (22).
In this study, we established a novel tRCC PDX preclinical model to serve as a platform for 
improving our understanding of this disease. We performed molecular characterization 
studies, including RNA-seq, ChIP-seq, miRNA expression profiling by RT-PCR, and 
immunodetection techniques. We applied the molecular signatures of our tRCC PDX model 
to generate hypothesis regarding potentially targetable pathways involved in oncogenesis 
using bioinformatic pathway analysis tools. We subsequently assessed the therapeutic 
potential of inhibiting an identified dysregulated pathway in tRCC using both in vitro and in 
vivo studies.
Materials and Methods
Methods patient derived xenograft RP-R07t generation.
The studies presented were conducted in accordance with the Declaration of Helsinki, and 
after approval by the RPCI Institutional Review Board and obtaining written consent from 
the subject. Non-necrotic areas of lymphoid metastatic nodule from a tRCC patient were 
sectioned into ~4 mm3 pieces. Fragments of the tumor containing both malignant cells and 
supportive stromal components, were implanted subcutaneously into the flanks implanted 
subcutaneously into anaesthetized 5-week to 6-week-old female NSG mice (The Jackson 
Laboratory, USA). During the engraftment phase, tumors were allowed to establish and 
grow and then were harvested upon reaching a size of 1,500 mm3. Harvested tumor was 
divided for three purposes: 1) patient derived cell line; 2) subsequent expansion through 
serial passaging in NSG mice: 3) biological assays for histological and molecular 
characterization of established PDX. The mice (P1 generation) were maintained under 
pathogen-free conditions and a 12-hour light/dark cycle. When P1 tumors reached an 
approximate size of 1800 mm3, they were harvested, fragmented, and reimplanted into 
additional mice (P2 generation) while maintained as a live bank according to approved 
Institutional Animal Care and Use Committee protocols. When enough P2 reached a volume 
greater than 200 mm3, the animals were divided into 4 groups (Vehicle, Rapamycin, 
MLN0128 and BEZ-235).
Patient derived cells RP-R07.
RP-R07 tumor pieces (∼4 mm2) were placed in a 6 wells culture plate and removed after 
being cultured for 24 hours in supplemented DMEM high glucose media (10% FBS; 1% 
penicillin/streptomycin). Adherent cells were a mixed population of tumor cells and 
fibroblasts. These cells were cultivated with feeder cells and supplemented with ROCK 
inhibitor until approximately 80% confluent. Serial passaging of these heterogeneous 
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cultures was performed, until a homogeneous monolayer of RP-R07 cells was present. RP-
R07 cell were subsequently cultured in DMEM medium (Gibco) supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin at 37°C, 5% CO2. The UOK109 and 
UOK146 cell lines were established by Dr. Linehan’s laboratory at the NCI (3).
Fusion detection by RNA-seq.
The RNeasy mini kit (Qiagen) was used for the isolation of RNA according to the 
manufacturer’s instructions. Site specific reverse transcription was performed with the 
reverse transcriptase Superscript III (Invitrogen) and five 3’ primers spaced throughout the 
TFE3 transcript. Following reverse transcription and subsequent second strand synthesis, the 
sequencing library for fusion detection was generated using an Illumina TruSeq sample 
preparation protocol for single-end reads. Reads were aligned using TopHat with Bowtie1 
and the fusion search option selected. Finally, tophat fusion post was used to identify 
putative fusion transcripts with a minimum of 3 supporting fusion reads.
Fusion validation by RT-PCR.
Total RNA was extracted by TRIzol (Invitrogen) according to manufactures instructions. 
Two microgram of RNA was used to perform cDNA synthesis by iScript cDNA synthesis kit 
(Bio-Rad) and then subjected to PCR reactions. To detect hybrid transcripts the resulting 
cDNA was subject to amplification with the SFPQ exon 7 primer 5′-
CGTCAACGTGAGATGGAAGA-3′ (forward primer) and the exon 6 TFE3 primer 5′-
GCAGGAGTTGCTGACAGTGA-3′ (reverse primer) for SFPQ-TFE3, PRCC exon 1 primer, 5′-
AGGAAAGAGCCCGTGAAGAT-3′ (forward primer) and TFE3 exon 6 primer, 5′-
GTTCTCCAGATGGGTCTGC-3′ (reverse primer) to detect PRCC-TFE3 and NONO exon 9 
primer, 5′-ATCAAGGAGGCTCGTGAGAA-3′ (forward primer) and TFE3 exon 6 primer, 5′-
GTTCTCCAGATGGGTCTGC-3′ (reverse primer) to detect NONO-TFE3. In these analysis, all 
reverse transcribed samples gave an β-actin PCR product of the expected size. The 
amplification conditions were 93°C for 20 s, 58°C for 40 s and 72°C for 40 s for 35 cycles in 
a final volume of 25 μl. The products were separated by electrophoresis in agarose gels 
followed by staining with ethidium bromide.
ChIP-seq and analysis.
ChIP was performed as previously describe (23). Cells were crosslinked using 1% v/v 
Formaldehyde (Fisher Scientific) for 15 minutes before quenching with 2M glycine for 5 
minutes. Cells were sonicated for 3 minutes (30 sec ON, 30 sec OFF) using a Diagenode 
Bioruptor Pico water bath sonicator. Following sonication, the lysate was rotated with the 
TFE3 antibody (P16: sc-5958, Santa Cruz, USA) for 4 hours at 4°C before subsequent 
washing and DNA isolation by phenol-chloroform. Library preparation was performed as 
previously describe (24). Reads were aligned to the genome with Bowtie before duplications 
and hg19 blacklisted reads were removed. Peak calling was performed using Macs v1.4.2, 
and following peak calling, nearest neighboring genes were determined using the Useq 
platform (http://useq.sourceforge.net/). Enriched motifs were determined using the MEME-
ChIP software within the MEME Suite online package for all called TFE3 binding sites.
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Total RNA extraction for miRNA expression screening.
Total RNA isolation was done using the miRNeasy Kit (Qiagen, Mississauga, Canada) 
according to the manufacture’s protocol. RNA quality and concentration were determined 
spectrophotometrically (NanoDrop 1000 Spectrophotometer; NanoDrop Technologies Inc., 
Wilmington, Delaware). Samples optimal for analysis were stored at −80˚C.
miRNA expression screening by TaqMan Low Density Array Cards.
500 ng total RNA from each sample were reverse transcribed using a Megaplex Primer Pool 
Human Set A+B (Life Technologies) with a TaqMan® miRNA reverse-transcription kit as 
suggested by the manufacturer. cDNA samples of individual patients were analyzed by a 
TaqMan® low-density array human microRNA card set A+B. Relative expression was 
determined using the ΔΔCT method and expression values were normalized to small nuclear 
RNA, U6 snRNA, RNU48 and RNU44.
MTT cell proliferation assay.
RP-R07, UOK-109 and UOK-146 cells (3000 cells/well) were seeded in 96-well plates and 
incubated for 24 h at 37 °C and 5% CO2. The following day, cells were treated with drugs 
with defined concentrations. All drugs for in-vitro study sunitinib (LC laboratories), USA), 
gemcitabine (LC laboratories), USA), doxorubicin (LC laboratories), USA), crizotinib (LC 
laboratories), USA), BKM-120 (Novartis, USA), MLN0128 (Millenium, USA) and NVP-
BEZ235 (Novartis, USA) were dissolved in DMSO for the preparation of stock solutions 
(10mM). Cell viability was determined by measuring dehydrogenase activity. We changed 
the medium and applied 100 μL of serum-free medium with 25 μL of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5 mg/mL) to each well and 
incubated the cells for 4 h at 37 °C and 5% CO2 to allow the formation of a purple formazan 
salt. The medium was replaced with 100 μL of methanol to dissolve the formazan crystals 
and the plates were incubated for a further 15 min at room temperature before the 
absorbance was measured at λ = 570 nm using a Micro Plate Reader (BioTek Synergy HTX, 
USA).
Histology/Immunohistochemistry.
Mice were sacrificed by CO2 asphyxiation at defined time points. Collected tumor tissue 
was fixed in 10% buffered formalin overnight followed by an additional 24 hours in 70% 
ethanol. Formalin Fixed Embedded Tissue was cut using microtome with 10 um thickness. 
Tissue slides were dried overnight and subjected to de-paraffinization in xylene. For antigen 
retrieval, slides were boiled for 10 minutes in 10 mM sodium citrate pH 6 solution for all 
antibodies. ImmPRESS detection system (Vector Laboratories) was used for detection of 
TFE3 (TFE3 (P-16): sc-5958, Santa Cruz, USA). Staining was visualized using 3,3′-
Diaminobenzidine (DAB) (Sigma, Saint Louis, MO, FAST 3,3′-Diamino benzidine) and 
slides were counterstained with hematoxylin.
Immunofluorescence microscopy.
Cells grown on glass coverslips with and without drug treatment were washed with PBS and 
fixed with 4% paraformaldehyde on ice for 15 min. After fixation, cells were washed with 
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PBS and then permeabilized with 0.1% Triton X-100 in PBS at room temperature for 20 min 
followed by blocking with 2.5% Bovine Serum Albumin (BSA) in PBS for 90 minutes. 
Cells were then incubated with the indicated primary antibodies; rabbit anti phospho-
ribosomal S6 Ser235/236 (Cell signaling technology, #2211, at 10ug/mL), rabbit anti 
phospho-4EBP-1 (Cell signaling technology #2855 and #9451, at 20ug/mL), rabbit anti 
phosphor-AKT (ser473) (Cell signaling technology #4060 at 10ug/mL), Mouse anti IRS-2 
(Millipore #MAB S15 at 10 ug/mL), rabbit anti LDH (Santa Cruz Biotechnology #sc-33781 
at 10ug/mL), rabbit anti TFEB (Bethyl Laboratory #A303–673A at 10 ug/mL), rabbit anti 
TFEC ( Sigma #AV32279), rabbit anti N-terminal TFE3 (Santa Cruz Biotechnology 
#sc-33781) and IR in IF buffer (PBS containing 2.5% BSA and 0.1% triton X-100) 
overnight at 4o Celsius temperature. Cells were washed three times with PBS and incubated 
with the corresponding secondary antibodies conjugated to Alexa Fluor 633-conjugated goat 
anti-mouse IgG or Alexa Fluor 633-conjugated goat anti-rabbit IgG (1:2,000; Life 
Technologies) in IF buffer for 30 min at room temperature. PBS washed coverslips were 
mounted onto glass slides with Vectashield antifade mounting medium (Vectorlabs, USA). 
Images were acquired on EVOS-FLc AMEFC4300 fluorescence imaging system 
(Thermoscientific, USA) with the same acquisition parameters for each group. Images taken 
were processed and quantified with ImageJ software (NIH).
SiRNA mediated TFE3 silencing.
Cells were transfected with siRNAs targeting TFE3, (Silencer® Select siRNAs, Sigma 
#s14032, USA) or a scrambled siRNA (Silencer™ Select Negative Control No. 1 siRNA, 
Sigma #4390843, USA). RP-R07 cells were cultured in 6-well plates until 50%−60% 
confluence, transfected with TFE3-siRNA or scramble with a final concentration 100 nM 
using Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen #13778075, USA) 
according to the manufacturer’s instructions. At 72 h after transfection, cells were harvested 
for qRT-PCR or Immunofluorescence analyses.
In vivo animal treatments.
The Institute Animal Care and Use Committee at Indiana University approved all mouse 
protocols used in this study. Mice were housed in a BSL-2 level animal facility maintained 
on a 12-h light/dark cycle, at a constant temperature (22±2°C) and relative humidity 
(55±15%). NSG mice for in-vivo study were purchased from an in-house colony maintained 
at Indiana University. Approximately six-week old NSG mice were implanted 
subcutaneously with ~ 3 mm3 pieces of RP-R07 tumor and allowed to grow until tumors 
reached 200 mm3 in volume prior to treatment with either vehicle, Rapamycin (EMD 
chemicals, USA), MLN0128 (kindly provided by Millenium Pharmaceuticals, USA) or 
BEZ-235 (kindly provided by Novartis Pharmaceuticals, USA). Tumor bearing mice 
received therapy with Rapamycin (2 mg/kg daily; i.p. injection). MLN0128, (3 mg/kg, three 
times a week; i.p. injection), BEZ-235 (25 mg/kg daily-five days per week; oral gavage) or 
vehicle (daily-five days per week; oral gavage). Throughout the study all mice receiving 
therapy were weighed twice weekly to monitor for toxicities. Tumor growth was assessed by 
serial caliper measurements twice weekly.
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Statistical Analysis
Statistical analysis was performed GraphPad (San Diego, CA, USA) prism software. 
Differences among experimental groups were tested by Student’s t test or for variances by 
ANOVA followed by Tukey post-test. P-values less than 0.05 were considered to be 
statistically significant.
RESULTS
Establishment of RP-R-07t patient-derived xenograft (PDX) model.
A 24-year-old Caucasian male patient with no previous medical history presented with a 
symptomatic, large tumor mass in the right kidney. The patient underwent nephrectomy 
which revealed a high grade, mixed clear cell/papillary RCC. Further analysis driven by his 
young age led to the diagnosis of MiT family tRCC associated with an Xp11.2 translocation/
TFE3 gene fusion by FISH analysis. The patient developed rapidly growing metastases, 
initially in the lymph nodes and lungs. Therapies with a vascular endothelial growth factor 
receptor tyrosine kinase inhibitor (sunitinib), a mTOR inhibitor (everolimus), and 
chemotherapeutic drugs (doxorubicin and gemcitabine), had no effect on tumor progression 
and eventually the patient deceased within one year from diagnosis.
During the course of the disease, we obtained a lymph node biopsy (Fig. 1A). The resected 
tissue was partitioned into ~3–5 mm3 pieces, processed, and implanted subcutaneously into 
six-week-old female NOD-SCID gamma (NSG) mice. We allowed tumors to grow to a size 
of ~1,500 mm3 during the engraftment phase, at which point they were harvested for the 
following purposes: 1) establishment of a cell line, 2) further expansion through serial 
passaging in NSG mice (Fig. 1B), and 3) histological and molecular characterization. To 
develop the RP-R07 cell line, we adopted a conditional reprogramming method utilizing 
Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor and irradiated 
NIH-3T3 murine fibroblasts . We evaluated whether our PDX pre-clinical model maintained 
histological features of the original lymph node metastasis. The cellular architecture in our 
PDX tumor model remained remarkably faithful to the tumor original morphology (Fig. 1C), 
exhibiting similar mixed papillary and clear cells characteristics. Furthermore, our PDX 
model demonstrated the same strong TFE3 nuclear immunoreactivity observed in the 
original biopsy.
Identification of SFPQ-TFE3 fusion in RP-R07 by RNA-seq.
To identify the specific TFE3 fusion gene and chromosomal breakpoint in our pre-clinical 
model, we sequenced RNA isolated from RP-R07 cells. Reverse transcription using multiple 
oligonucleotides complementary to TFE3 was followed by next generation sequencing to 
characterize TFE3 fusion transcripts. A fusion transcript was identified spanning the SFPQ 
gene on chromosome 1p and the TFE3 gene on chromosome Xp. The genomic coordinates 
of the RNA fusion junction localized to specific chromosomal break-points 
(Chr1:35652601; ChrX:48895638) (Fig. 1D). This location corresponds to the end of SFPQ 
exon 9 and the beginning of TFE3 exon 5. The expression of the SFPQ-TFE3 fusion 
transcript was confirmed by subjecting cDNA from RP-R07 to RT-PCR amplification with 
5’-SFPQ and 3’-TFE3 primers and, as a control, primer sets for the NONO-TFE3 (25) and 
Damayanti et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PRCC-TFE3 fusions (26). Only the SFPQ-TFE3 hybrid transcript with a predicted size of 
375bp was observed in RP-R07 (Fig. 1E), while the NONO-TFE3 and PRCC-TFE3 fusions 
were not detected. Using the same SFPQ-TFE3 primers, we did not detect the presence of 
the SFPQ-TFE3 transcript in the NONO-TFE3 fusion-bearing UOK-109 cell line (25) (Fig. 
1F), the PRCC-TFE3 fusion-bearing UOK-146 cell line (26), the UMR-C2 ccRCC cell line, 
or the HK-2 human renal cell tubule cell line.
TFE3 nuclear expression is characteristic of tRCC.
Xp11.2 tRCC contains fusion genes that encode chimeric proteins consisting of the N-
terminal portion of different translocation or inversion partners fused to the C-terminal 
portion of TFE3 (3). Therefore, chromosomal rearrangements involving the TFE3 gene at 
Xp11.2 are characterized by strong nuclear immunoreactivity for the C-terminal portion of 
TFE3 regardless of TFE3 fusion gene partner (27). We identified enhanced nuclear 
immunoreactivity of C-terminal TFE3 in three different tRCC models: RP-R07 (SFPQ-
TFE3), UOK-109 (NONO-TFE3), and UOK-146 (PRCC-TFE3). In contrast, nuclear 
immunoreactivity was low in the ccRCC cell line, UMR-C2 (Fig. 1G). However, despite the 
common presence of C-terminal TFE3 immunoreactivity, each tRCC model demonstrated 
distinct expression levels and distribution patterns. Co-localization analysis (Fig. 1H) 
represents the level of C-terminal TFE3 nuclear localization. The UOK-109 model showed 
the highest C-terminal TFE3 nuclear immunoreactivity with a dense expression pattern 
(R=0.78, UOK-109-UMR-C2 P<0.0001). RP-R07 demonstrated moderate C-terminal TFE3 
nuclear immunoreactivity with a diffuse expression profile (R=0.69, RP-R07-UMR-C2 
P<0.0001). Whereas, the UOK-146 model demonstrated the lowest C-terminal TFE3 nuclear 
immunoreactivity with a mixed expression pattern involving diffuse and speckle components 
(R=0.62, UOK-146-UMR-C2 P<0.0001).
ChIP-seq based TFE3-DNA binding profiling reveals TFE3 occupancy of genomic regions 
with consensus E-box motifs both in vitro and in vivo.
We performed ChIP-seq to explore the DNA binding landscape of TFE3 in RP-R07 (patient 
derived cells) and RP-R07t (patient derived xenograft) and UOK-146 cells. The Western blot 
result demonstrates the specificity of the antibody recognizing TFE3 in all three cells RP-
R07, UOK-146 and UOK-109 (Supplementary Fig. S1). ChIP-seq in RP-R07 cells identified 
3032 significant TFE3 peaks. ChIP-seq from RP-R07t identified 856 significant TFE3 peaks 
(Supplementary Table S1, Table S2). A comparison of TFE3 ChIP-seq signal across all 
bound regions revealed a strong overlap between RP-R07 and RP-R07t (Fig. 2A), indicating 
that the in vitro and in vivo model have similar TFE3 binding profiles. Furthermore, we have 
also observed identical binding profile of TFE3 in UOK-146 cells (Supplementary Fig. S2). 
An unbiased search for over-represented sequence motifs in TFE3-bound regions by 
MEME-ChIP identified the known TFE3 target E-box motif (CACGTGA) as the most 
enriched motif in both cell line and tumor samples (Fig. 2B). Notably, AP-1 (TGACTCA) 
and ETS (AGGAA) binding motifs are the second and third most enriched motifs in TFE3 
bound regions in the cell line. The identified TFE3 peaks distribution in RP-R07 and RP-
R07t are presented in Supplementary Fig. S3 and Fig. S4, respectively.
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TFE3 target genes are associated with the PI3K/AKT/mTOR signaling pathway.
We applied our ChIP-seq results to study the molecular pathways targeted by the SFPQ-
TFE3 fusion gene product using pathway analysis bioinformatics tools, including KEGG, 
PANTHER, and WIKI. Comprehensive panels of 287 KEGG pathways, 96 PANTHER 
pathways, and 403 WIKI tools pathways associated with the SFPQ-TFE3 fusion gene 
product are listed in Supplementary Table S3, Supplementary Table S4, and Supplementary 
Table S5, respectively. Based on these results, we noted that the PI3K/AKT/mTOR axis was 
consistently ranked as a top significantly influenced pathway in all three analysis methods 
(Fig. 2C-E). When looking closely at our ChIP-seq results, we were able to identify of 
SFPQ-TFE3 targeted genes related to the PI3K/AKT/mTOR pathway, such as PI3KCA, 
TSC1, AKT3, PTEN, 14–3-3, ITGB1, IGFR1, and IRS-1 (Fig. 2F).
MicroRNAome landscape profiling reveals molecular pathway signatures of RP-R-07.
After profiling the TFE3 transcriptional architecture in our tRCC model, we further studied 
its post-transcriptional microRNAome landscape. Expression profile analysis of the whole 
microRNAome in tRCC (RP-R07t), ccRCC and pRCC PDX models (also established in our 
lab) was performed using TaqMan® low-density array human microRNA card set A+B. 
These are pre-loaded arrays with TaqMan Gene Expression Assays for mature miRNAs. 
Despite overlapped histological features of ccRCC and pRCC PDX in our tRCC PDX (Fig. 
3A), several miRNAs showed variable expression among the three varied subtypes (Fig. 3B). 
Unsupervised hierarchical clustering employing one minus Pearson correlation with average 
linkage further classified tRCC, ccRCC, and pRCC into three well-defined clusters and 
differentially expressed miRNA into nine well-defined clusters (Fig. 3C). Cluster 3 had the 
greatest deviation of miRNA expression, with a > 2-fold change of expression in our tRCC 
model as compared to ccRCC and pRCC PDX models (Fig. 3D). To further understand the 
biological impact of differentially expressed miRNA in our tRCC model, we used DIANA-
miRPath to perform a pathway analysis of the miRNA in cluster 3. Hierarchical clustering 
heatmap revealed significantly targeted pathways by the miRNA signature in cluster 3 (Fig. 
3E). The top significantly enriched pathways based on the number of miRNA targeted genes 
associated with each pathway (Fig. 3F) were “Pathways in cancer” (P=1.11E-16), “PI3K-
Akt signaling pathway” (P=4.91E-09), “Proteoglycans in cancer” (1.11E-16), “Focal 
adhesion” (P=6.26E-10), “Viral carcinogenesis” (P=1.11E-16), “MAPK signaling pathway” 
(P=0.000121), and “Hippo signaling pathway” (P=1.11E-16). A complete list of the 
statistically enriched pathways targeted by differential expression of miRNA in cluster 3 is 
available in Supplementary Table S6. Enriched KEGG PI3K/AKT signaling pathway 
visualization (Supplementary Fig. S5) shows that almost all predicted genes in this pathway 
are targeted by aberrantly expressed miRNA in cluster 3, including PI3KCA, AKT1, IRS1, 
RPS6, TSC1, eIF4BP1, and mTOR among others. A complete list of targeted genes in the 
PI3K/AKT signaling pathway with their associated miRNA from cluster 3 is reported in 
Supplementary Table S7.
Upregulation of PI3K/AKT/mTOR pathway in tRCC.
The PI3K/AKT (28) and mTOR (29) signaling pathways function interdependently to 
regulate cellular growth, proliferation, angiogenesis, and survival. Their roles are so 
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intertwined such that they are often unified into one unique signaling axis, PI3K/AKT/
mTOR. Oncogenic dysregulation of this pathway has been implicated in a variety of tumors, 
including ccRCC (30). Thus, we were interested in testing whether this pathway is also 
involved in tRCC, starting with the examination of P13K/AKT/mTOR activity in our tRCC 
panel. Phosphorylation of S6 ribosomal protein (S6rp) and 4E-BP1 occurs at the end of the 
P13K/AKT/mTOR signaling cascade to facilitate translation. Thus, by measuring the 
immunoreactivity of phosphorylated S6rp (31) and 4E-BP1, we can gauge the level of 
P13K/AKT/mTOR activation. Using a quantifiable immunofluorescence technique, our 
results suggest a higher level of phospho-S6rp (Fig. 4A, C) expression in the tRCC cell lines 
as compared to the ccRCC cell line. The expression levels of phospho-4E-BP1 in the tRCC 
cell lines were also higher than those observed in the ccRCC cell line as well (Fig. 4B, D). 
These results suggest that the PI3K/AKT/mTOR pathway is disproportionately upregulated 
in tRCC regardless of TFE3 gene fusion partner.
Effective in vitro multi-nodal P13K/AKT/mTOR inhibition in RP-R07.
Based on the dysregulation of the P13K/AKT/mTOR pathway, we tested the anti-tumor 
effect of inhibiting this pathway in tRCC cell lines, as a potential therapeutic strategy. We 
designed three vertical inhibition schemas to target the PI3K/AKT/mTOR axis at different 
points within the pathway: 1) PI3K/AKT axis inhibition with the P13K inhibitor BKM-120, 
2) m-TOR axis inhibition with the pan-mTOR inhibitor MLN0128, and 3) simultaneous 
inhibition of the PI3K/AKT and mTOR axis with the dual P13K/mTOR inhibitor BEZ-235. 
We first examined whether the drug response profiles of our tRCC panel were reflective 
of the lack of response to anti-neoplastic agents that the patients experienced. RP-R07, UOK 
109, and UOK-146 cells were exposed to increasing concentrations of sunitinib, 
doxorubicin, and gemcitabine for 96 hours (Fig. 4E-G). The tRCC cell lines were relative 
insensitive to these anti-neoplastic agents except for gemcitabine. Thus, we evaluated our 
multi-nodal PI3K/AKT/mTOR inhibition strategy in vitro. An MTT assay was performed 
after cells were treated with different concentrations of BKM-120, MLN0128, rapamycin or 
BEZ-235 for 96 hours to assess the anti-tumor activity of these agents (Fig. 4H-J, 
Supplementary Fig. 6). BKM-120 treatment inhibited cellular proliferation in a 
concentration-dependent manner with IC50 values of 420, 373.6 and 714 nM for RP-R07, 
UOK-109, and UOK-146, respectively (Fig. 4K). The dual TORC1/TORC2 inhibitor 
MLN0128 demonstrated greater anti-proliferative effect than the PI3K inhibitor BKM-120 
with 10-fold lower IC50 values (RP-R07: IC50=49.4 nM, UOK-109: IC50=24.3 nM, and 
UOK-146: IC50=8.18 nM). Treatment with dual PI3K/mTOR inhibitor BEZ-235 had the 
lowest IC50s in our tRCC panel (RP-R07: IC50=12.2 nM, UOK-109: IC50=13.41 nM, and 
UOK-146: IC50= 7.03 nM). Taken together, these results suggest that simultaneous vertical 
inhibition of the PI3K/AKT/mTOR axis with a dual PI3K/mTOR inhibitor provides a 
greater anti-proliferative effect in vitro as compared to P13K/AKT or mTOR inhibition 
alone for the treatment of tRCC.
Attenuation of PI3K/AKT/mTOR downstream targets by BEZ-235.
To validate whether the anti-proliferative effect of BEZ-235 in RP-R07 cells was associated 
with biochemical attenuation of the PI3K/AKT/mTOR pathway, we assessed the 
phosphorylation and expression levels of selected key nodes by immunofluorescence. 
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BEZ-235 treatment inhibited phosphorylation of 4EBP-1 at Serine-65 (78% inhibition; 
P<0.0001) and Threonine-37 (58% inhibition: P<0.0001) (Fig. 5A, B). Corresponding signal 
reduction of phosphorylated AKT at Serine-473 (27% inhibition; P<0.001) and 
phosphorylated S6rp at Serine 240/244 (63.3% inhibition; P<0.0001) was also observed. 
Additionally, we observed decreased expression of PI3K/AKT/mTOR possible downstream 
target such as lactate dehydrogenase (54.4% inhibition; P<0.0001), IRS-1 (33.9% inhibition; 
P<0.0001), TFE3 (24.1% inhibition; P<0.0001), TFEB (53% inhibition; P<0.0001) and 
TFEC (41% inhibition; P<0.0001).
TFE3 silencing attenuates PI3K/AKT/mTOR signaling and suppresses IRS-1 expression 
and cell proliferation in RP-R07.
We have shown that wild type TFE3 is a potential downstream target of PI3K/AKT/mTOR 
axis as PI3K/mTOR inhibition suppresses TFE3 expression. Therefore, to further determine 
whether TFE3 inhibition by PI3K/AKT/mTOR directly affects cellular biological function, 
we assessed the effect of siRNA mediated TFE3 silencing on RP-R07 cell proliferation. 
First, we confirmed the efficacy of our siRNA treatment by assessing TFE3 endogenous 
mRNA transcript level and protein expression after cells treatment with TFE3-siRNA and 
negative control-siRNA, scramble RNA (Fig. 6A). Further, decrease of protein expression 
levels of TFE3 following TFE3-siRNA treatment was observed by immunofluorescence 
(Fig. 6B, C). Next, we assessed whether inhibition of TFE3 provides regulatory feedback on 
PI3K/AKT/mTOR signaling axis. Decrease expression of phospho-4EBP1 (Fig. 6D, F) and 
phospho-S6 ribosomal (Fig. 6E, G) was observed in TFE3-siRNA treated cells compared to 
scramble RNA treated cells. This result suggests the possible regulatory role TFE3 on 
PI3K/AKT/mTOR pathway via a feedback loop mechanism in which TFE3 is not only 
downstream target of PI3K/AKT/mTOR pathway, but also directly regulates this signaling 
pathway. As far as the regulatory mechanism of TFE3 on PI3K/AKT/mTOR pathway, we 
propose that this may be mediated through TFE3 target genes which are upstream effectors 
of this signaling axis. Based on our ChIP-seq results (Fig. 2F, Supplementary Table 2), TFE3 
binds to IRS-1, an upstream effector of PI3K/AKT/mTOR (32). Therefore, we further 
validated the transcriptional regulatory role of TFE3 on IRS-1 by assessing the effect of 
TFE3 inhibition on IRS-1 expression. SiRNA mediated silencing of TFE3 decreased 
endogenous expression of IRS-1 mRNA transcript compared to scramble RNA treatment 
(P<0.01) (Fig. 6H). Next, the analysis of immunofluorescence images further demonstrated 
the decrease of IRS-1 protein expression following TFE3-siRNA treatment compared to 
scramble RNA treatment (P<0.001) (Fig. 6I, J). Finally, TFE3 silencing inhibited cell 
proliferation of RP-R07 in a time-dependent fashion (Fig. 6K). Following TFE3-siRNA 
treatment at 96 hrs and 110 hrs, the cell number was significantly reduced (96 hrs P=0.04, 
110 hrs P< 0.00001) in RP-R07 compared to the non-silencing control siRNA transfected 
cells and non-treated cells.
Effective in vivo multi-nodal P13K/AKT/mTOR inhibition in RP-R07.
Next, we investigated the anti-proliferative effect of MLN0128 and BEZ-235 in vivo. We 
also wanted to assess the efficacy of rapamycin, an mTOR complex-1 (mTORC1) inhibitor, 
as a comparator since the mTOR inhibitors that are FDA approved in the treatment of RCC, 
everolimus and temsirolimus, have a similar mechanism of action (33). Everolimus and 
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temsirolimus have shown limited clinical activity in RCC (34–37), in part due resistance 
mechanism(s) via mTORC2-mediated rebound AKT hyperphosphorylation. Therefore, we 
postulated that MLN0128 and BEZ-235 could provide superior anti-tumor effects as 
compared to rapamycin given their ability to impact this resistance pathway. To test these 
drugs, NSG mice bearing subcutaneously implanted RP-R07 xenografts were treated with 
MLN0128 (3 mg/kg), rapamycin (2 mg/kg), or BEZ-235 (25 mg/kg) for 28 days. The 
vehicle and treatment group mice (5 mice per group) maintained their body weight 
throughout, incurring in modest weight loss (Supplementary Fig. S7). Treatment of RP-R07 
xenografts with MLN0128, rapamycin, and BEZ-235 resulted in decreased tumor weight 
(Fig. 6L) compared to the vehicle control. However, only treatment with BEZ-235 resulted 
in a statistically significant lower tumor weight when compared to vehicle control (P<0.01). 
RP-R07t cells of the tumor in the BEZ-235 treated group appeared smaller than those in the 
vehicle (Fig. 6M), indicating inhibition of mTOR pathway (38). The proliferation marker 
Ki67 was reduced in the BEZ-235 treated group as compared to the untreated control (Fig. 
6M, N), indicating inhibition of cell cycle (90% inhibition, P<0.0001). The in vivo 
immunostaining replicated the in vitro results demonstrating that BEZ-235 significantly 
reduced the phosphorylation level of S6 ribosomal protein (83% inhibition, P<0.0001) (Fig. 
6M, O). The analysis of microvessel density, as measured by CD31 staining, revealed 
significant inhibition of tumor angiogenesis in BEZ-235 treated RP-R07 tumors (56% 
inhibition at day 28; P<0.0001) compared to vehicle (Fig. 6M, P). Overall, these data 
suggest the therapeutic efficacy of a multi-nodal P13K/AKT/mTOR inhibition strategy for 
TFE3-tRCC (Supplementary Fig. S8).
DISCUSSION
Therapeutic strategies to effectively treat MiT family translocation renal cell carcinoma have 
yet to be established. More importantly, there is a clinical need for evidence-based 
treatments, as a significant number of patients, likely underestimated by histological 
misclassification, may be afflicted by this subtype of RCC. In our study, we have 
characterized the DNA binding landscape of a TFE3 gene fusion product by ChIP-seq using 
our recently established PDX model bearing a SFPQ-TFE3 fusion. TFE3 binding to 
genomic regions containing E-box motif was confirmed, and 3032 TFE3 binding sites were 
associated with 2213 putative TFE3 target genes. Interestingly, our ChIP-seq data also 
indicate TFE3 binding on ETS and AP-1 binding sites. TFE3 binding on ETS binding motif 
is consistent with previous reports (3), while TFE3 binding on AP-1 binding site has not 
been previously reported. ETS and AP-1 binding sites are known to be enriched at enhancers 
of genes that promote epithelial-mesenchymal transition and cellular migration and invasion 
(24). Pathway analysis using KEGG, PANTHER and Wiki tools identified the PI3K/AKT/
mTOR axis as the top significantly influenced pathway. Specific TFE3 target genes were 
also associated with this pathway, such as PI3KCA, AKT3, IRS-1, TSC-1, EIF4B, 
VEGFR-2, suggesting that the PI3K/AKT/mTOR axis represents a rational therapeutic 
target for this disease.
MicroRNAs (miRNA) are small RNA molecules with 19–23 nucleotide length which act as 
either tumor promoters or tumor suppressors by targeting the transcription and translation of 
specific genes. The differential miRNA signature in ccRCC compared to normal kidney 
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tissues has been well established, and specific miRNAs differences have been identified in 
metastatic ccRCC (39) (20). We used microarray technology to evaluate the miRNA 
expression profile of our tRCC model, and observed a distinct miRNA expression profile as 
compared to pRCC and ccRCC models, despite the presence of mixed papillary/clear cell 
histologic features. Our results are consistent with recent miRNA profiling of Xp11 tumors 
bearing SFPQ-TFE3 and ASPSCR1-TFE3 (40), demonstrating distinct miRNA profiles 
against published data set of ccRCC and pRCC (41). Interestingly, despite different tumor 
panels and slight difference in our clustering algorithm and method, we also found that 
tRCC miRNA expression profile is closer to ccRCC compared to pRCC (40). Moreover, our 
bioinformatic tools indicated that the differential expression of miRNAs could be linked to 
several targets genes and pathways. Consistent with our ChiP-seq data, PI3K/AKT/mTOR 
was identified once again as a pathway with significant (P=4.91E-9) association with the 
miRNA signatures in RP-R07. Similar predicted miRNAs target genes associated with the 
PI3K/AKT/mTOR pathway, as seen in ChIP-seq, were identified as well. It is noteworthy 
that some pathways associated with differential miRNA expression identified in our study 
are the same miRNA associated pathways identified in previous work (40) using larger panel 
of tRCC tumors. These miRNAs associated pathways include PI3K pathway, cell cycle, p53, 
lysine degradation, erbB signaling, and wnt signaling pathway. However, different pathways 
identified in our analysis may due to the fact that the tRCC tumor panels involved in 
previous work consisted of SFPQ-TFE3 and ASPSCR1-TFE3 tumors while we focused on a 
SFPQ-TFE3 model. Aberrant activation of PI3K/AKT/mTOR pathway itself has been 
reported in RCC (42). Although previous studies have demonstrated the association of AKT/
mTOR pathway (3) and upregulated phosphor-S6 (43) with tRCC, our results further support 
the role of PI3K/AKT/mTOR pathway in tRCC as a potential target for therapeutic 
interventions.
Data integration of tRCC molecular signatures is a valuable resource to generate new 
hypotheses regarding therapeutic targeted pathways. Therefore, we used a panel of tRCC 
models to test the hypothesis whether inhibition of the PI3K/AKT/mTOR axis would lead to 
anti-tumor response. First, we verified that the P13K/AKT/mTOR signaling is overexpressed 
in our tRCC panel by upregulation of phospo-S6rp and phospho-4E-BP1 protein expression. 
Then, we enacted a variable, multi-nodal P13K/AKT/mTOR inhibition strategy using three 
treatment arms to examine the effects of blocking this pathway at different points in vitro 
and in vivo: 1) PI3K inhibition with BKM-120, 2) pan-mTOR inhibition with MLN0128, 
and 3) simultaneous vertical inhibition of PI3K and mTOR with BEZ-235. While all three 
treatment arms had a greater anti-proliferative effect as compared to the MET inhibitor 
crizotinib, BKM-120 had a modest effect, which is possibly due to inadequate inhibition by 
targeting PI3K axis alone. In contrast, MLN0128 and BEZ-235 potently inhibited 
proliferation of all tRCC cells models tested in a concentration-dependent fashion, with 
BEZ-235 exerting the greatest effect. While the three therapeutic agents had similar 
treatment trends across our tRCC panel, there were differential IC50 values amongst the 
tRCC models bearing distinct TFE3 gene fusions. The tRCC models included in our study 
did not show a significant response to the MET inhibitor crizotinib. These results seem to be 
in contrast with previous work (44) that suggests an inhibitory effect of MET inhibition in a 
tRCC model with ASLP-TFE3 fusion. One possible explanation for this difference is that 
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MET upregulation may be specific for ASPL-TFE3 fusion and our tRCC panels do not have 
ASPL-TFE3 fusion. These results may also imply differential regulatory pathways in a 
fusion partner-dependent fashion and support previous report with differential cathepsin-k 
expression in tRCC(45). Thorough discussion and analysis on the role of MET inhibition 
strategy in tRCC has been recently reported (3). BEZ-235 was the only treatment that 
resulted in significant tumor reduction in vivo compared to the modest tumor growth 
inhibition by rapamycin or MLN0128 alone. Even though dual mTOR inhibition with 
MLN0128 conferred greater efficacy of tumor growth inhibition compared to partial mTOR 
inhibition, possibly due to attenuation of the mTORC2-AKT reactivation mechanism (46), 
our results suggest that neither form of mTOR blockade in isolation is sufficient to elicit 
significant tumor control in TFE3-tRCC. These results corroborate our finding in the clinic 
where the patient did not benefit from single agent treatment with everolimus, a mTOR 
inhibitor, suggesting the need of alternative therapeutic strategy such as simultaneous PI3K 
and mTOR inhibition.
Interestingly, tRCC does not present a high mutational burden, as the clinical aggressiveness 
might suggest (47). As previously reported in tRCC, RP-R-07 tumor did not carry mutations 
in canonical genes such as TP53, VHL, PIK3CA, RAS, PTEN, as per the clinical report. 
(48). The absence of subtype-specific chromosomal abnormalities, besides the fusion genes, 
suggests a potential “driver” role of TFE3 in the oncogenesis and response to therapies of 
tRCC. By using siRNA mediated TFE3 silencing strategy, we showed that attenuated wild 
type TFE3 expression exerts inhibitory effect on RP-R07 cell proliferation. These data also 
suggest that dimerization with wild type TFE3 is probably required for the biological effects 
of chimeric TFE3. Next, we also showed possible feedback regulatory mechanism of TFE3 
on PI3K/AKT/mTOR by demonstrating inhibition of PI3K/AKT/mTOR downstream 
effectors following TFE3-siRNA treatment. To further investigate TFE3 feedback loop 
regulatory mechanism on PI3K/AKT/mTOR, we examined TFE3 target genes based on our 
ChIP-seq results. One of TFE3 target genes was IRS-1, an upstream modulator of 
PI3K/AKT/mTOR axis (3). Using the same TFE3 silencing strategy, we confirmed our 
ChIP-seq result that TFE3 transcriptionally regulates IRS-1. Furthermore, we showed that 
TFE3 silencing inhibits IRS-1 expression. IRS-1 is one of upstream effectors of PI3K/AKT/
mTOR pathway which is negatively controlled by p70S6 kinase (49). However, our study 
suggests an alternative positive regulation of IRS-1 by TFE3 that likely bypasses P70S6K 
regulation, and ultimately results in PI3K/AKT/mTOR aberrant activation. Collectively, our 
results suggest that targeting PI3K/AKT/mTOR results in TFE3 inhibition, and, ultimately, 
attenuates its feedback loop activation by downregulating its transcriptional target, IRS-1, 
one of upstream modulators of the pathway. Although, there is possibility that TFE3 
feedback loop mechanism on PI3K/AKT/mTOR may be achieved through other upstream 
nodes of this signaling axis.
In summary, TFE3 tRCC remains a therapeutic challenge (3). Despite the common mixed 
clear cell and papillary cell morphology, the reported clinical response to targeted therapies, 
including VEGF receptor tyrosine kinase and mTOR inhibitors, is modest (50). The results 
from the use of immune checkpoint inhibitors are still not available. Overall, our results 
suggest the therapeutic potential of PI3K/AKT/mTOR inhibition in tRCC patients. We 
identified that simultaneous vertical inhibition targeting PI3K and mTOR had greater anti-
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tumor response than single node PI3K or mTOR inhibition. However, due to reported 
toxicity of BEZ-235 (51), further investigation of the safety and therapeutic potential of 
PI3K/AKT/mTOR inhibition in tRCC patients as well as efforts to develop new PI3K/AKT/
mTOR inhibitors with lower toxicities are need.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Glossary
The abbreviations used are:
tRCC translocation renal cell carcinoma
ccRCC clear cell renal cell carcinoma
pRCC papillary renal cell carcinoma
PDX patient-derived xenograft
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
alpha
ChIP-Seq chromatin immune precipitation sequencing
miRNA microRNA
MiT Micropthalmia transcription factor
NGS next generation sequencing
RT-qPCR quantitative reverse transcription polymerase chain reaction
IRS-1 insulin receptor substrate 1
NSG NOD-SCID gamma
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TRANSLATIONAL RELEVANCE
Despite the significant progress achieved by targeted therapies in renal cell carcinoma, 
patients with translocation RCC continue do have a poor outcome. The lack of 
understating of the biology of this aggressive subtype remains a major hurdle for the 
development of effective therapies. Thus, we have discovered a key signaling pathway 
activated by the transcriptional factor TFE3 as the result of the pathognomonic genomic 
alteration in translocation RCC. Therefore, we have identified an effective combination 
strategy that can be readily translated to patients with this orphan, deadly disease.
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Figure 1. Generation of a patient derived xenograft (PDX) RP-R07t and RP-R07 cells from a 
tRCC patient.
A. Schematic diagram of development of PDX as a model for therapeutic strategies in the 
treatment of tRCC patients. B. PDX model demonstrates its ability to self-propagate. B. 
Growth of primary tumor graft is represented as tumor volume versus time after 
implantation. Different color indicated different passages. At least four mice were included 
in each group. C. Faithful resemblance of cellular complexity, architecture and molecular 
signature of PDX tumor to the patient tumor. Hematoxylin-eosin staining revealed that the 
PDX model (bottom) recapitulates the histologic appearance of patient tumor, showing 
characteristic phenotype of mixed papillary architecture and clear or eosinophilic cytoplasm, 
nested alveolar pattern, voluminous cytoplasm, prominent nucleoli and the presence of 
psammoma bodies. Molecular signature of X11p translocation, immunoreactivity of nuclear 
TFE3, is observed in patient biopsy sample (top right) and is preserved in PDX model 
(bottom right). D. TFE3 fusion architecture by RNA-seq. In-frame fusion transcripts were 
identified with the chromosomal coordinates corresponding to the fusion position indicated 
in red (GRCh37/hg19) and the fusion sequence in grey. E. PCR fusion validation in RP-R07 
using SFPQ-TFE3, NONO-TFE3, and PRCC-TFE3 primers, F. PCR validation in RP-R07, 
UOK-109, UOK-146, UMR-C2 and HK2 using SFPQ-TFE3 primer. G. Nuclear 
Immunoreactivity of TFE3 is exclusive for tRCC. Immunofluorescence profile of patient 
derived cells and cell line stained with the same TFE3 (internal epitope sc-4784) antibody 
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shows positive nuclear immunoreactivity of TFE3, identified with co-localization (grey 
white) of nuclear TFE3 (cyan) with DNA stain Hoechst (red) in tRCC cells; RP-R07, 
UOK-146 and UOK-109 and lower expression (P<0.005) of nuclear TFE3 in RCC cell line 
UMR-C2 H. Co-localization analysis by measuring Pearson correlation coefficient (R) 
between green channel (TFE3) and red channel (Hoechst) indicating strong nuclear 
localization of TFE3 in tRCC (R>0.5), and significantly lower expression of nuclear TFE3 
in UMR-C2. (R < 0.5, P<0.005). H. Quantitative analysis.
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Figure 2. Profiling of TFE3-DNA binding landscape in RP-R07 and RP-R07t by ChIP-seq.
A. Heatmap comparison of TFE33 binding in RP-R07 and RP-R07t at all sites called as 
bound in either sample. B. The three most enriched sequence motifs identified by the 
MEME-ChIP program for TFE3 bound regions in RP-R07 or RP-R07t. (C-E). Top 12 
pathways associated with TFE3 target genes identified by C. KEGG, D. PANTHER and E. 
WIKI tools. F. Selected TFE3-targeted genes associated with PI3K/AKT/mTOR pathway.
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Figure 3. MicroRNA profiling of RP-R07t.
A. IHC staining of RP-R07, pRCC and ccRCC PDX. B. Heatmap showing 786 differential 
miRNA expression profile. C. Hierarchical clustering of miRNAs expression separate tRCC 
subtype from pRCC and tRCC D. Number of differentially expressed RP-R07t’s miRNA 
with >2-fold change compared to pRCC and or ccRCC in each cluster in C. E. miRNAs 
versus pathways heatmap (clustering based on significance levels). F. Top significant KEGG 
pathway associated with differentially expressed miRNA based on the number of associated 
miRNA target genes.
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Figure 4. Simultaneous vertical inhibition of PI3K/AKT and mTOR pathways in tRCC.
A. PI3K/AKT/m-TOR pathway upregulation in tRCC. Representative immunofluorescence 
images of fixed tRCC cells; RP-R07, UOK-109, UOK-146 and ccRCC cell, UMR-C2, 
stained with: A. anti-phospho S6 (red) and anti F-actin (green), and Hoechst (blue); B. anti-
phospho 4EBP-1 (red) and Hoechst (blue) and corresponding quantification (C, D). E-J. RP-
R07 exhibits similar chemoresistance as observed in the patient. Three different tRCC cells, 
RP-R07, UOK-109, and UOK-146 were treated for 96 hours with indicated concentrations 
of different drugs. Cell growth was assessed by MTT assay and absorbance was measured at 
589 nm. Each dot and error bar on the curves represents mean ± standard deviation (s.d.) (n = 
8). All experiments were repeated at least three times. K. IC-50 Value of agent in H to J. 
BEZ-235 has the lowest IC-50 compared to other agents.
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Figure 5. BEZ-235 treatment associates with attenuation of PI3K/AKT/mTOR pathway.
A. Immunofluorescence images of p-4EBP-1(ser 65), p-4EBP-1 (Thr37), pS6, p-AKT 
(S473), LDH, IRS-1, TFE3. TFEB, TFEC in BEZ-235 treated RP-R07 cells. B. 
Immunofluorescence quantification and student-t test analysis.
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Figure 6. TFE3 transcriptionally regulates IRS-1, an upstream effector of PI3K/AKT/mTOR, 
and its downregulation inhibits RP-R07 cells proliferation.
°Evaluation of TFE3 knockdown by siRNA by qRT-PCR and by immunofluorescence. A. 
TFE3 mRNA expression level in RP-R07. B. Immunofluorescence quantification and 
student t-test analysis. C. Immunofluorescence images of N-terminal TFE3 in RP-R07. 
siRNA mediated silencing of TFE3 downregulates PI3K/AKT/mTOR downstream effectors 
4EBP-1 (D, F) and S6 ribosomal (E, G) activity. Immunofluorescence quantification, student 
t-test analysis and representative immunofluorescence images. siRNA mediated silencing of 
TFE3 downregulates IRS-1 at the RNA-level (H) and protein level (I, J). 
Immunofluorescence quantification, student t-test analysis and representative 
immunofluorescence images. K. TFE3-siRNA inhibited RP-R07 cell proliferation. Graph 
represents cells number concentration (cells/mL) after treatment with no siRNA, siRNA 
control (scramble) and TFE3-siRNA (siTFE3) at 50 nM for 24 hours (siTFE3 vs scramble 
P= 0.74), 48 hours (siTFE3 vs scramble P= 0.38), 72 hours (siTFE3 vs scramble P= 0.13), 
96 hours (siTFE3 vs scramble P= 0.04) and 110 hours (siTFE3 vs scramble P<0.0001). (L-
P) Dual inhibition of PI3K-mTOR by BEZ-235 results in anti-tumor activity in vivo. RP-
R07 cells (5×106) were injected subcutaneously into the flank of male SCID mice. Mice 
bearing RP-R07 xenograft tumors (n=5 for each group) were randomized into four groups (L 
1. Vehicle 2. MLN0128 (3mg/kg) 3. Rapamycin (2 mg/kg) and 4. BEZ235 (25 mg/kg). No 
apparent drug toxicity was observed for each treatment. All mice were weighed twice 
weekly to monitor drug toxicities (i.e. ≥20% body weight loss). Dual inhibition PI3-mTOR 
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therapy significantly inhibits tumor growth. L. Average tumor weight (gram) in SCID mice 
treated with indicated single agent. Only tumors from mice treated with BEZ-235 was 
significantly smaller (P<0.001, One Way ANOVA, multiple comparison) than tumor from 
mice treated with vehicle. (M) Dual inhibition of PI3-mTOR by single agent BEZ-235 
inhibits angiogenesis and attenuates PI3K-mTOR signaling in-vivo. Representative 
immunofluorescence images of paraffin embedded RP-R07 tumor slice (8 um) treated with 
vehicle (top) and BEZ-235 (bottom) stained with; anti Ki67 (left), anti-phosphoS6 ribosomal 
(middle), and angiogenesis marker CD31 (right). (N-P) Quantitative analyses.
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